APA (7th ed.) Citation

J, B., K, K., CY, C., R, B., JC, C., T, F., . . . MV, H. (2021). Response to comment on "Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics". Science translational medicine, 13(622), eabf4530. https://doi.org/10.1126/scitranslmed.abf4530

Chicago Style (17th ed.) Citation

J, Bovijn, et al. "Response to Comment on "Evaluating the Cardiovascular Safety of Sclerostin Inhibition Using Evidence from Meta-analysis of Clinical Trials and Human Genetics"." Science Translational Medicine 13, no. 622 (2021): eabf4530. https://doi.org/10.1126/scitranslmed.abf4530.

MLA (9th ed.) Citation

J, Bovijn, et al. "Response to Comment on "Evaluating the Cardiovascular Safety of Sclerostin Inhibition Using Evidence from Meta-analysis of Clinical Trials and Human Genetics"." Science Translational Medicine, vol. 13, no. 622, 2021, p. eabf4530, https://doi.org/10.1126/scitranslmed.abf4530.